R&G PharmaStudies Co (301333.SZ) Stock Price
R&G PharmaStudies Co Price
Over the last 6 years R&G PharmaStudies Co grew revenue by 12.2% annually, reaching 848.06 M CNY. Earnings per share have grown at 8.8% per year over the last 6 years. For R&G PharmaStudies Co, the net margin of 16.1% is broadly stable versus 16.3% a few years ago. At today's price the dividend yield works out to roughly 0.27%. The payout ratio is around 11% of earnings. The consensus 12-month price target for R&G PharmaStudies Co is 67.83 CNY, about 14.0% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
R&G PharmaStudies Co stock price
R&G PharmaStudies Co business model & stock analysis
Frequently asked questions about R&G PharmaStudies Co
Analysts currently set an average price target of 67.83 CNY for the R&G PharmaStudies Co stock (median: 67.83 CNY), implying +14.0 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the R&G PharmaStudies Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect R&G PharmaStudies Co to generate revenue of 975.00 M CNY and earnings per share of 1.73 CNY.
Converted at the current exchange rate, the R&G PharmaStudies Co share trades at 7.93 EUR (59.50 CNY).
The expected revenue of R&G PharmaStudies Co is 975.00 M CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of R&G PharmaStudies Co is 167.08 M CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of R&G PharmaStudies Co is currently 34.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the R&G PharmaStudies Co stock.
The price-to-sales ratio (P/S) of R&G PharmaStudies Co is currently 5.89. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the R&G PharmaStudies Co stock.
The Eulerpool Quality Score for R&G PharmaStudies Co is 4/10.
The ISIN of R&G PharmaStudies Co is CNE100005K44. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of R&G PharmaStudies Co is 301333.SZ. The ticker symbol is used to trade R&G PharmaStudies Co shares on the stock exchange.
R&G PharmaStudies Co stock
R&G PharmaStudies Co Peer Group
R&G PharmaStudies Co FIGI
All fundamentals and in-depth analysis of R&G PharmaStudies Co
Our stock analysis for R&G PharmaStudies Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of R&G PharmaStudies Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.